Mr. Hu is a well-known entrepreneur and also a professional manager with proactive thinking. He has been investing in China since 1996 starting while he was leading China Development Industrial Bank (CDIB). During the period of 1993-2004, he grew the investment portfolio from $ 250MM to $ 3.0Bn, making CDIB one of Asia′s largest investment companies. He expanded business of the bank to the United States, Great Britain, Japan, Hong Kong, Korea, Australia, and Philippines.
Of the 250 companies invested during tenure, 62 companies had IPOs and 10 were acquired. In 2003, he assumed role as Chairman and Director of Taipei 101, the tallest building in the world when completed in 2004. Mr. Hu is currently Chairman of Senhwa Biosciences, Inc. dedicating to develop first-in-class small molecule drugs used in cancer treatments.
Mr. Hu received a BA from National Taiwan University, an MA from Yale University and an MBA from Wharton School of University of Pennsylvania.
Jin-Ding Huang, PhD
Dr. Huang joined Senhwa as a board director in March 2022. In May, he was taken the role of Chief Scientific Officer and appointed to Chief Executive Officer in October to lead the company.
Dr. Huang has more than 30 years of experience in the biotech-pharmaceutical industry, academia and official. He served as the chairman of drug approval committee of Taiwan Food and Drug Administration, the vice dean at College of Medicine, National Cheng Kung University, Taiwan, and the CEO of Eusol Biotech Co., Ltd.
Dr. Huang holds a doctorate degree from the School of Pharmacy at the University of California. Dr. Huang was awarded the Fellow of the American Association of Pharmaceutical Scientists (AAPS), the Fellow of the Japanese Society of Pharmacokinetics (JSSX) and the domestic first-class education medal for his outstanding research contributions.
Sarah Chang, CPA
Ms. Chang joined Senhwa in 2013 and is currently Vice President, Chief Finance Officer and Head of Finance and Administration. She brings Senhwa 15 years of experience in finance and accounting. Before joining Senhwa Biosciences, Inc., Ms. Chang was the Vice President of Operating group (CFO&COO) of Hua Nan Investment Trust Corporation, the large mutual fund company in Taiwan. She was Senior Vice President of the Underwriting Department at IBT Securities Co., Ltd. and lead the IPO project and pre-IPO consultation. Ms Chang is a Certified Public Accountant and also worked at Deloitte & Touche.
She graduated with Accounting major from Tunghai University
Tzu-I Chao, Ph.D.
Dr. Chao joined Senhwa in September 2023. He is currently serving as the director of drug development, with a focus on assessing and advancing our drug development projects. Dr. Chao brings a multifaceted experience in drug development, including a solid track record in pre-clinical anti-cancer research, and his oversight role in the oncology clinical trial. His proficiency extends to development, management, and business activities within the industry. He was a core member in the development of a drug formulation for clinical trial applications. He had also been deeply involved in the execution of a co-development agreement for an anti-cancer agent, which bridged two biotech firms from different countries.
Dr. Chao received his Ph.D. degree from University of California, Merced, and pursued his postdoctoral training at University of California, Davis. Prior to joining Senhwa, Dr. Chao held positions at SupremeCure Pharma.
Kacy Huang
Ms. Huang joined the Senhwa team in August 2015. She is currently Head of Clinical Department. Her core responsibilities are the coordination and management of clinical trial development in the US and Taiwan.
Ms. Huang's diverse experience brings rich professional knowledge of pharmacy practices, clinical pharmacy, regulation, clinical trial operations to her role as Head of Clinical Department. Prior to Senhwa, Ms. Huang held positions in regulation affairs and pharmacist at North Cross Pharmacy, National Taiwan University Hospital, Taisho Pharmaceutical (Taiwan), among others.
Ms. Huang graduated with a degree in Pharmacy from the University of Auckland, and is a licensed pharmacist in both Taiwan and New Zealand.
Chen-Fu Liu, PhD
Dr. Liu joined Senhwa in November, 2017 and appointed as Director leading R&D department. He is well experienced in drug discovery team structure, patent strategy, CMC and formulation development in the pharmaceutical industry for more than 15 years.
Dr. Liu obtained his Ph.D. degree in chemistry from National Taiwan University in 2002. Since then, he joined TaiGen Biotechnology as a post-doc fellow in the department of medicinal chemistry and served as an investigator afterwards. After TaiGen, Dr. Liu accumulated his solid knowledge and experience in the industry with GNT Biotech & Medicals Corporation, GNTbm and took in charge for the CMC & formulation development while 2 drug candidates were at the stage of phase 2b of multi-national and multi-centered clinical operation when he worked in CVie Therapeutics Limited. Dr. Liu also was the member of the steering committee of a joint collaboration between CVie and ScinoPharm on identifying a new generation of heart failure treatment.
Dr. Liu was certificated with Winston & Strawn LLP American Patent Law and University of Washington Seattle, school of law, CASRIP 2015 program (MMOT program). Further, Dr. Liu holds 5 PCT patents and many of his scientific publications were highly recognized.
Irene Chiu, CIA
Ms. Chiu joined Senhwa in 2021 and served as Internal Audit Supervisor since January 2021. She came to Senhwa with many years of experience as Internal Auditor. She worked as auditor firstly in KPMG, and later in Litemax Electronics Inc.
She graduated with Accounting major from Tamkang University.
Gwen Chang
Ms. Chang joined the Senhwa team in October 2016, as the President Office Executive Assistant and also handling Media and Public Relations. Ms. Chang is acquired abundant background integrating from Public Relations, Media and Human Resource. She possessed 10+ year in Media industry as reporter, anchor, producer and correspondent in Mainland China and 5+ year in human resource management field as career consultant in a Singaporean headhunting firm and Standard Chartered Bank as senior recruiting manager.
Ms. Chang received Postgraduate Diploma in Journalism Studies from Strathclyde University, Glasgow, UK, Bachelor Degree in Foreign Languages from National Chung Hsing University.
Joanne Lo, PhD
Ms. Lo joined Senhwa in May, 2021 and appointed as Business Development Director, responsible for increasing company revenue by identifying and developing new business opportunities as well as expanding brand presence. Ms. Lo has possessed more than 10 years of experience in pharmaceutical industry with specialty in market research and analysis, product management and business development. She has proven track records in business development of the companies she served including Oneness Biotech Co. Ltd., Abbott Laboratories Services Corp. Taiwan Branch, Lumosa Therapeutics Co., Ltd., etc.
Ms. Lo received her Ph.D. degree in ClinicalPharmacy from NCKU-National Cheng Kung University, Taiwan, a BS (Honors) in Biochemistry from McGill University, Montreal, Quebec, Canada.
Jocelyn Lee
Ms. Lee joined Senhwa in August 2023 and currently serves as the Director of Legal and Regulatory Affairs. She is responsible for drug registration strategies and brings over 10 years of extensive regulatory experience in the biopharmaceutical industry. Ms. Lee excels in assisting with licensing assessment, regulatory execution and planning, as well as project management for new drugs. She is well-versed in European and US regulatory frameworks. Previously, Ms. Lee worked as a pharmacist at Mackay Memorial Hospital and as the head of the Regulatory Department at TTY Biopharma, demonstrating outstanding performance and achievements.
Ms. Lee graduated from the School of Pharmacy at Taipei Medical University and obtained her master's degree in Medicine from Taipei Medical University. She is a licensed pharmacist in Taiwan.
Daniel McCormick
Mr. McCormick joined Senhwa in 2017 and is currently Director of Clinical Operations. He is responsible for working across functional groups to operationalize Senhwa’s clinical development plans. He brings 15 years of industry experience, specializing in early phase oncology and hematology clinical trial management, regulatory strategy, and financial stewardship. Before joining Senhwa, Mr. McCormick developed a robust knowledge in GCPs while working for PPD, a large global CRO. While employed, he raised the ranks and ultimately assigned to a newly established strategic partnership with Pfizer. This assignment required him to serve as a first-user responsible for developing processes and training for all subsequent clinical trials under the partnership.
Mr. McCormick received an undergraduate degree at the University of North Carolina, Wilmington, USA.
Ruby Wu
Ms. Ruby Wu first joined Senhwa in 2013, as the Internal Audit Supervisor for both the Taiwan Office and the US Office during the developing stage of internal control. After the company was listed in the Emerging Stock Market, the Board of Directors appointed her to a new role, managing the operations of the US Office in San Diego. Since then, her duties have continued to expand over time. She is currently overseeing human resources, finance, legal and compliance, information technology, and general affairs of the US Office. She also serves as the primary contact for external stakeholders, and is acting as liaison between the Taiwan and US Offices.
A Certified Internal Auditor (CIA), Ms. Wu received her B.B.A. in Finance from National Taiwan University, and holds an M.S. in Marketing from Baruch College, City University of New York.
